FAQ: NanoViricides $6 Million Registered Direct Offering and Corporate Overview
Summary
NanoViricides announced a $6 million registered direct offering with concurrent private placement of warrants to a healthcare institutional investor, with proceeds intended for working capital and general corporate purposes. This funding supports the company's clinical-stage development of broad-spectrum antiviral nanomedicines, including their lead drug candidate NV-387.
What is the main announcement in this press release?
NanoViricides announced a $6 million registered direct offering with concurrent private placement of warrants to a single healthcare institutional investor, involving the purchase of 3,571,429 shares at $1.68 per share.
How much money is NanoViricides raising and how?
The company expects gross proceeds of approximately $6 million before expenses through a registered direct offering of common stock at $1.68 per share, along with concurrent private placement of Series A and Series B warrants.
What are the details of the warrants being issued?
The company will issue Series A warrants exercisable at $1.75 per share (expiring in 2 years) and Series B warrants exercisable at $2.00 per share (expiring in 5.5 years), with both becoming exercisable six months after issuance.
When is the offering expected to close?
The closing of the offering is expected on or about November 12, 2025, subject to customary closing conditions.
How will the company use the proceeds from this offering?
Proceeds will be used for working capital and general corporate purposes to support the company’s operations and development programs.
Who is involved in facilitating this offering?
A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction, and the securities are being purchased by a single healthcare institutional investor.
What is NanoViricides’ primary business focus?
NanoViricides is a clinical-stage company developing broad-spectrum antiviral nanomedicines using proprietary nanoviricide technology licensed from TheraCour Pharma, Inc.
What are NanoViricides’ lead drug candidates?
The lead drug candidate is NV-387 for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, while NV-HHV-1 is being developed for Shingles treatment.
What is the company’s current clinical development focus?
The company is currently focused on advancing NV-387 into Phase II human clinical trials for various viral infections.
Where can I find more detailed information about this announcement?
The full press release is available at https://ibn.fm/neQCh, and additional company information can be found on their website at www.nanoviricides.com.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 281154